Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00322764 · ClinicalTrials.gov registry record · Phase 2
Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression
A Phase 2 study of Bipolar Depression, sponsored by Repligen Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 11
- Study locations
NCT00322764 is a Phase 2 study of Bipolar Depression that has completed, run by Repligen Corporation. The registered enrollment target is 80 participants, below the 213-participant average among 29 other Bipolar Depression trials with a reported enrollment target (62% lower). The trial reports 11 study locations across 8 states.
The verdict
NCT00322764, a Phase 2 study of Bipolar Depression, has completed, sponsored by Repligen Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 11
- Study locations
Study Summary
The primary purpose of this study is to determine the safety and efficacy of oral RG2417 (Uridine) when administered to patients with Bipolar I depression twice daily for six weeks.
Conditions Studied
Interventions
- DRUG Uridine
Study Locations (11)
Texas
- Future Search Trials of Austin - Austin
- Future Search Trials of Dallas - Dallas
- University of Texas Health Science Center at San Antonio - San Antonio
Ohio
- University of Cincinnati - Cincinnati
- Cleveland Clinic Foundation - Cleveland
California
- Stanford University - Stanford
Georgia
- Carman Research - Smyrna
Indiana
- Indiana University-Purdue University Indianapolis - Indianapolis
Maryland
- Marc Hertzman, MD, PC - Rockville
Massachusetts
- Massachusetts General Hospital - Boston
New York
- Medical & Behavioral Health Research, PC - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2006-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00322764
The ClinicalTrials.gov registry entry for NCT00322764 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 213-participant average among 29 other Bipolar Depression trials with a reported enrollment target (62% lower). The listed sponsor is Repligen Corporation, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bipolar Depression appearing as the primary indexed condition, and to 1 intervention - of which Uridine is the first listed.
NCT00322764 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Texas, Ohio, California.
Frequently Asked Questions
What is clinical trial NCT00322764 about?
NCT00322764 is a clinical study titled "Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression". The primary purpose of this study is to determine the safety and efficacy of oral RG2417 (Uridine) when administered to patients with Bipolar I depression twice daily for six weeks.
What is the current status of trial NCT00322764?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2006-03.
What conditions does trial NCT00322764 study?
This clinical trial studies the following conditions: Bipolar Depression.
What interventions are being tested in trial NCT00322764?
The interventions under investigation include: Uridine (DRUG).
Who is sponsoring clinical trial NCT00322764?
This trial is sponsored by Repligen Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00322764 being conducted?
This trial has 11 study locations across California, Georgia, Indiana, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression
COMPLETED · Phase 2
-
Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder
RECRUITING · Early Phase 1
-
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
RECRUITING · Phase 3
-
University of Iowa Interventional Psychiatry Service Patient Registry
RECRUITING
-
Ketogenic Intervention for Bipolar Depression
RECRUITING · NA
-
RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.